Printer Friendly

Printed from

Vietnam Pharmaceuticals and Healthcare Report Q1 2009

Vietnam Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on Vietnam's pharmaceuticals and healthcare industry.

Vietnam’s US$1.2bn pharmaceutical market is one of the most promising long-term prospects in our coverage universe. Annual per capita consumption of pharmaceuticals is low; however, we are forecasting a compound annual growth rate (CAGR) of 17.6% through to 2013.

We believe that Vietnam's ambition to have a fully subscribed national health insurance plan in place by 2014 will be achieved before that date. The country's GDP is increasing rapidly, and the desire for universal membership has been displayed by both the state and potential policy holders. It is our opinion that the October 2008 announcement that premiums will be determined using a means test methodology was critical in garnering support for the programme from those on low income.

The vast majority of hospitals in Vietnam are large state-owned facilities that are frequently overcrowded and generally offer only basic services. There are a growing number of private facilities that offer advanced services, but many local people on high incomes still travel abroad for healthcare. According to the General Statistics Office of Vietnam, there were a total of 956 hospitals in the South East Asian country during 2007, up from 842 in 2003.

Demonstrating the sector’s rapid development, construction on Vietnam’s first applied biotechnology research centre started in September 2008. A total of VND530bn (US$32mn) will be spent on the project, which will cover 200 hectares. The centre will investigate biological solutions to agricultural problems and unmet medical needs. Completion of construction is expected in 2010.

Sao Kim Company became the first Vietnamese drugmaker to receive Good Manufacturing Practice (GMP) certification from the World Health Organization (WHO) in October 2008. The company met with all of the WHO's GMP standards in pharmaceutical materials and received all certificates of GMP certification relating to both materials and products. It also received Good Laboratory Practice (GLP) and Good Safety Practice (GSP) certificates.

Cancer is becoming increasingly prevalent in Vietnam. The main drivers are growing cigarette and alcohol consumption, the Westernisation of diets, worsening air quality, urbanisation and more people adopting a sedentary lifestyle. This is a trend seen in all countries, but Vietnam is not coping with the increasing burden well. We believe that there will be a growing opportunity for drugmakers and medical device firms as the government begins to tackle the problem.
Executive Summary 5
Vietnam Pharmaceutical And Healthcare Industry SWOT 6
Vietnam Political SWOT 7
Vietnam Economics SWOT 8
Vietnam Business Environment SWOT 9
Vietnam – Business Environment Rankings10
Table: Asia Pacific Pharmaceutical Business Environment Rankings For Q109 10
Limits Of Potential Returns 10
Risks To Realisation Of Returns 11
Market Summary 12
Regulatory Regime14
Pharmaceutical Advertising 14
Intellectual Property Environment 15
IP Shortcomings 15
Counterfeit Drugs 17
Other Regulatory Issues 17
Pricing And Reimbursement Regime 18
Industry Trends And Developments 20
Epidemiology 20
Healthcare Financing 23
Healthcare Insurance 24
Healthcare And Pharmaceutical Reforms 25
Foreign Partnerships 26
Domestic Pharmaceutical Sector 27
Recent Pharmaceutical Industry Developments 28
Foreign Pharmaceutical Sector 29
Traditional Medicines 30
Retail Sector 30
Table: Key Aspects Of Good Pharmacy Practice (GPP) In Developing Countries 31
Research And Development 31
Vaccine Sector 32
Biotechnology Sector 33
Industry Forecast Scenario 35
Overall Market Forecast 35
Table: Vietnam – Pharmaceutical Expenditure, 2003-2013 36
Key Growth Factors – Industry 37
Key Growth Factors – Industry 37
Table: Vietnam – Health Expenditure, 2003-2013 38
Key Growth Factors – Macroeconomic 39
Table: Vietnam – Economic Activity 41
Prescription Market Forecast 42
Table: Vietnam – Prescription Market Indicators, 2003-2013 (VNDmn unless otherwise stated) 43
OTC Market Forecast 44
Table: Vietnam – OTC Medicine Expenditure, 2003-2013 (VNDmn unless otherwise stated) 45
Patented Market Forecast 46
Patented Market Forecast 46
Table: Vietnam – Patented Product Expenditure, 2003-2013 47
Generic Market Forecasts 48
Table: Vietnam – Generics Drug Expenditure, 2003-2013 49
Export/Import Forecasts 50
Table: Vietnam – Pharmaceutical Trade Indicators, 2003-2013 (US$mn) 51
Medical Device Market Forecast 52
Table: Vietnam’s Medical Device Market (US$mn unless otherwise stated) 54
Other Healthcare Data Forecasts 55
Table: Vietnam – Other Healthcare Indicators, 2003-2012 55
Key Risks To BMI’s Forecast Scenario 56
Competitive Landscape57
Company Profiles58
Leading Multinational Manufacturers 58
Pfizer 58
GlaxoSmithKline 60
Sanofi-Aventis 62
Novartis 64
Merck & Co 65
Indigenous Manufacturer Profiles 66
Vietnam Pharmaceutical Corporation (Vinapharm) 66
Vietnam OPV Pharmaceutical Co 68
Stada Vietnam 70
Vietnam Pharmaceutical Joint Stock Company (Ampharco) 72
Vidipha Central Pharmaceutical Joint Stock Company 74
Country Snapshot: Vietnam Demographic Data75
Section 1: Population 75
Table: Demographic Indicators, 2005-2030 75
Table: Rural/Urban Breakdown, 2005-2030 76
Section 2: Education And Healthcare 76
Table: Education, 2002-2005 76
Table: Vital Statistics, 2005-2030 76
Section 3: Labour Market And Spending Power 77
Table: Employment Indicators, 1999-2004 77
Table: Consumer Expenditure, 2000-2012 (US$) 77
Forecast Modelling78
How We Generate Our Pharmaceutical Industry Forecasts 78
Pharmaceutical Business Environment Ratings Methodology 79
Ratings Overview 79
Table: Pharmaceutical Business Environment Indicators 80
Weighting 81
Table: Weighting Of Components 81
Sources 81
Companies Mentioned
-Merck & Co
-Vietnam Pharmaceutical Corporation (Vinapharm)
-Vietnam OPV Pharmaceutical Co
-Stada Vietnam
-Vietnam Pharmaceutical Joint Stock Company (Ampharco)
-Vidipha Central Pharmaceutical Joint Stock Company
Order Online - visit

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,

Page 1 of 2
Printed Feb 10, 2016
1:11:55 PM

Fax order form

To place a fax order simply print this form, fill in and fax the completed form to the number below. If you have any questions please email

Order information

Please verify that the product information is correct and select the format you require.

Product name

Vietnam Pharmaceuticals and Healthcare Report Q1 2009

Web Address

Office Code


Report Formats

Please enter the quantity of the report format you require.

Format Quantity Price
Electronic (PDF) - Single User USD 1,100

Contact information

Please enter all the information below in block capitals.

Mr Mrs Dr Miss Ms Prof
First Name:
Last Name:
Job Title:
Post/Zip Code:

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Page 2 of 2
Printed Feb 10, 2016
1:11:55 PM

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

Pay by Credit Card:

You will receive an email with a link to a secure page to enter your credit card details.

Pay by Check:

Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,

Pay by Wire Transfer:

Please transfer funds to:

Account Number:
Sort Code:
Swift Code:
Bank Address:
Ulster Bank,
27-35 Main Street
Co. Dublin

If you have a Marketing Code please enter it below:

Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)